Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Safety of Administering Intravenous CT Contrast Agents Repeatedly or Using Both CT and MRI Contrast Agents on the Same Day: An Animal Study

  • Heejin Bae (Department of Radiology, Severance Hospital, Yonsei University College of Medicine) ;
  • Hyewon Oh (Department of Radiology, Severance Hospital, Yonsei University College of Medicine) ;
  • Ga Bin Park (Department of Radiology, Severance Hospital, Yonsei University College of Medicine) ;
  • Yong Eun Chung (Department of Radiology, Severance Hospital, Yonsei University College of Medicine)
  • Received : 2023.07.27
  • Accepted : 2023.12.21
  • Published : 2024.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate molecular and functional consequences of additional exposures to iodine- or gadolinium-based contrast agents within 24 hours from the initial intravenous administration of iodine-based contrast agents through an animal study. Materials and Methods: Fifty-six Sprague-Dawley male rats were equally divided into eight groups: negative control, positive control (PC) with single-dose administration of CT contrast agent, and additional administration of either CT or MR contrast agents 2, 4, or 24 hours from initial CT contrast agent injection. A 12 µL/g of iodinated contrast agent or a 0.47 µL/g of gadolinium-based contrast agent were injected into the tail vein. Serum levels of blood urea nitrogen, creatinine, cystatin C (Cys C), and malondialdehyde (MDA) were measured. mRNA and protein levels of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were evaluated. Results: Levels of serum creatinine (SCr) were significantly higher in repeated CT contrast agent injection groups than in PC (0.21 ± 0.02 mg/dL for PC; 0.40 ± 0.02, 0.34 ± 0.03, and 0.41 ± 0.10 mg/dL for 2-, 4-, and 24-hour interval groups, respectively; P < 0.001). There was no significant difference in the average Cys C and MDA levels between PC and repeated CT contrast agent injection groups (Cys C, P = 0.256-0.362; MDA, P > 0.99). Additional doses of MR contrast agent did not make significant changes compared to PC in SCr (P > 0.99), Cys C (P = 0.262), and MDA (P = 0.139-0.771) levels. mRNA and protein levels of KIM-1 and NGAL were not significantly different among additional CT or MR contrast agent groups (P > 0.05). Conclusion: A sufficient time interval, probably more than 24 hours, between repeated contrast-enhanced CT examinations may be necessary to avoid deterioration in renal function. However, conducting contrast-enhanced MRI on the same day as contrast-enhanced CT may not induce clinically significant kidney injury.

Keywords

Acknowledgement

This work was supported by the faculty research grant from Yonsei University College of Medicine (grant number: 6-2021-0122).

References

  1. Hasebroock KM, Serkova NJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 2009;5:403-416
  2. Wichmann JL, Katzberg RW, Litwin SE, Zwerner PL, De Cecco CN, Vogl TJ, et al. Contrast-induced nephropathy. Circulation 2015;132:1931-1936
  3. European Society of Urogenital Radiology. ESUR guidelines on contrast agents 10.0 [accessed on May 25, 2022]. Available at: https://www.esur.org/wp-content/uploads/2022/03/ESUR-Guidelines-10_0-Final-Version.pdf
  4. American College of Radiology. ACR manual on contrast media 2022 [accessed on May 25, 2022]. Available at: https://www.acr.org/-/media/ACR/files/clinical-resources/contrast_media.pdf
  5. Mohammed NM, Mahfouz A, Achkar K, Rafie IM, Hajar R. Contrast-induced nephropathy. Heart Views 2013;14:106-116
  6. Tao SM, Wichmann JL, Schoepf UJ, Fuller SR, Lu GM, Zhang LJ. Contrast-induced nephropathy in CT: incidence, risk factors and strategies for prevention. Eur Radiol 2016;26:3310-3318
  7. Mitchell AM, Kline JA, Jones AE, Tumlin JA. Major adverse events one year after acute kidney injury after contrast-enhanced computed tomography. Ann Emerg Med 2015;66:267-274.e4
  8. Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 2008;3:263-272
  9. Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. Clin J Am Soc Nephrol 2010;5:4-9
  10. Park JH, Shin HJ, Choi JY, Lim JS, Park MS, Kim MJ, et al. Is there association between statin usage and contrast-associated acute kidney injury after intravenous administration of iodine-based contrast media in enhanced computed tomography? Eur Radiol 2020;30:5261-5271
  11. van der Molen AJ, Reimer P, Dekkers IA, Bongartz G, Bellin MF, Bertolotto M, et al. Post-contrast acute kidney injury - Part 1: definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 2018;28:2845-2855
  12. Abujudeh HH, Gee MS, Kaewlai R. In emergency situations, should serum creatinine be checked in all patients before performing second contrast CT examinations within 24 hours? J Am Coll Radiol 2009;6:268-273
  13. Trivedi H, Foley WD. Contrast-induced nephropathy after a second contrast exposure. Ren Fail 2010;32:796-801
  14. Geenen RW, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging 2013;4:811-820
  15. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol 2006;60:314-323
  16. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009;4:461-469
  17. Currie GM. Pharmacology, part 5: CT and MRI contrast media. J Nucl Med Technol 2019;47:189-202
  18. Akdeniz D, Celik HT, Kazanci F, Yilmaz H, Yalcin S, Bilgic MA, et al. Is kidney injury molecule 1 a valuable tool for the early diagnosis of contrast-induced nephropathy? J Investig Med 2015;63:930-934
  19. Wang ZY, Wang YL, Wei J, Jin L, Wang ZC. Role of serum cystatin C in the prediction of contrast-induced nephropathy after intra-arterial interventions. Chin Med J (Engl) 2020;133:408-414
  20. Quintavalle C, Anselmi CV, De Micco F, Roscigno G, Visconti G, Golia B, et al. Neutrophil gelatinase-associated lipocalin and contrast-induced acute kidney injury. Circ Cardiovasc Interv 2015;8:e002673
  21. Wacker-Gussmann A, Buhren K, Schultheiss C, Braun SL, Page S, Saugel B, et al. Prediction of contrast-induced nephropathy in patients with serum creatinine levels in the upper normal range by cystatin C: a prospective study in 374 patients. AJR Am J Roentgenol 2014;202:452-458
  22. Murty MS, Sharma UK, Pandey VB, Kankare SB. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian J Nephrol 2013;23:180-183
  23. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers 2021;7:52
  24. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet 2019;394:1949-1964
  25. Oh H, Choi A, Seo N, Lim JS, You JS, Chung YE. Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on post-contrast acute kidney injury. Sci Rep 2021;11:15625
  26. Oh SW, Park SY, Yong HS, Choi YH, Cha MJ, Kim TB, et al. Korean clinical practice guidelines for adverse reactions to intravenous iodinate and MRI-gadolinium contrast agents: revised clinical consensus and recommendations (3rd edition, 2022). J Korean Soc Radiol 2022;83:254-264
  27. Fahling M, Seeliger E, Patzak A, Persson PB. Understanding and preventing contrast-induced acute kidney injury. Nat Rev Nephrol 2017;13:169-180